Teladoc Health [TDOC] vs 10x Genomics [TXG] Detailed Stock Comparison

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Teladoc Health wins in 11 metrics, 10x Genomics wins in 7 metrics, with 0 ties. Teladoc Health appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricTeladoc Health10x GenomicsBetter
P/E Ratio (TTM)-1.50-8.5510x Genomics
Price-to-Book Ratio1.122.05Teladoc Health
Debt-to-Equity Ratio72.7811.2210x Genomics
PEG Ratio0.020.05Teladoc Health
EV/EBITDA103.14-11.0710x Genomics
Profit Margin (TTM)-8.16%-13.13%Teladoc Health
Operating Margin (TTM)-7.29%-2.63%10x Genomics
Return on Equity-14.18%-11.30%10x Genomics
Return on Assets (TTM)-3.57%-9.45%Teladoc Health
Free Cash Flow (TTM)$169.63M$-6.73MTeladoc Health
1-Year Return-1.20%-25.77%Teladoc Health
Price-to-Sales Ratio (TTM)0.632.46Teladoc Health
Enterprise Value$1.95B$1.23BTeladoc Health
EV/Revenue Ratio0.771.90Teladoc Health
Gross Profit Margin (TTM)69.85%72.34%10x Genomics
Revenue per Share (TTM)$15$5Teladoc Health
Earnings per Share (Diluted)$-1.15$-0.7010x Genomics
Beta (Stock Volatility)1.912.05Teladoc Health
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Teladoc Health vs 10x Genomics Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Teladoc Health8.60%16.54%15.94%6.82%26.96%-4.52%
10x Genomics4.05%-2.58%-13.35%-1.47%69.05%-14.94%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Teladoc Health-1.20%-60.75%-95.89%-49.50%-67.54%-67.54%
10x Genomics-25.77%-52.81%-92.63%-76.91%-76.91%-76.91%

News Based Sentiment: Teladoc Health vs 10x Genomics

Teladoc Health

News based Sentiment: MIXED

October was a month of conflicting signals for Teladoc, with continued financial challenges offset by a surprising stock surge and strategic initiatives. The regulatory environment remains a key risk, creating a mixed outlook for investors. The combination of positive market reaction and underlying financial concerns makes this a significant month for the company.

View Teladoc Health News Sentiment Analysis

10x Genomics

News based Sentiment: MIXED

October brought a strong Q3 earnings beat and positive analyst revisions for 10x Genomics, but these were tempered by a negative full-year EPS forecast and mixed technical indicators. This creates a complex investment picture with both opportunities and risks, making it a significant month for the company.

View 10x Genomics News Sentiment Analysis

Performance & Financial Health Analysis: Teladoc Health vs 10x Genomics

MetricTDOCTXG
Market Information
Market Cap i$1.59B$1.59B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i8,888,1602,746,660
90 Day Avg. Volume i5,961,5572,469,420
Last Close$9.09$12.07
52 Week Range$6.35 - $15.21$6.78 - $20.92
% from 52W High-40.24%-42.30%
All-Time High$308.00 (Feb 15, 2021)$208.99 (Jun 28, 2021)
% from All-Time High-97.05%-94.22%
Growth Metrics
Quarterly Revenue Growth-0.02%0.13%
Quarterly Earnings Growth-0.02%0.13%
Financial Health
Profit Margin (TTM) i-0.08%-0.13%
Operating Margin (TTM) i-0.07%-0.03%
Return on Equity (TTM) i-0.14%-0.11%
Debt to Equity (MRQ) i72.7811.22
Cash & Liquidity
Book Value per Share (MRQ)$8.05$6.21
Cash per Share (MRQ)$3.85$3.59
Operating Cash Flow (TTM) i$303.43M$66.95M
Levered Free Cash Flow (TTM) i$209.72M$58.22M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Teladoc Health vs 10x Genomics

MetricTDOCTXG
Price Ratios
P/E Ratio (TTM) i-1.50-8.55
Forward P/E i-10.12-10.45
PEG Ratio i0.020.05
Price to Sales (TTM) i0.632.46
Price to Book (MRQ) i1.122.05
Market Capitalization
Market Capitalization i$1.59B$1.59B
Enterprise Value i$1.95B$1.23B
Enterprise Value Metrics
Enterprise to Revenue i0.771.90
Enterprise to EBITDA i103.14-11.07
Risk & Other Metrics
Beta i1.912.05
Book Value per Share (MRQ) i$8.05$6.21

Financial Statements Comparison: Teladoc Health vs 10x Genomics

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)TDOCTXG
Revenue/Sales i$629.37M$154.88M
Cost of Goods Sold i$196.83M$49.44M
Gross Profit i$432.54M$105.45M
Research & Development i$69.96M$64.25M
Operating Income (EBIT) i$-54.94M$-48.53M
EBITDA i$50.34M$-32.89M
Pre-Tax Income i$-111.27M$-33.51M
Income Tax i$-18.26M$852,000
Net Income (Profit) i$-93.01M$-34.36M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)TDOCTXG
Cash & Equivalents i$679.62M$377.06M
Total Current Assets i$1.07B$579.73M
Total Current Liabilities i$401.77M$107.90M
Long-Term Debt i$1.03B$70.63M
Total Shareholders Equity i$1.42B$706.90M
Retained Earnings i$-16.36B$-1.50B
Property, Plant & Equipment i$27.67M$55.58M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)TDOCTXG
Operating Cash Flow i$89.56M$35.44M
Capital Expenditures iN/A$-1.89M
Free Cash Flow i$31.63M$32.46M
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricTDOCTXG
Shares Short i23.82M17.35M
Short Ratio i5.407.58
Short % of Float i0.15%0.22%
Average Daily Volume (10 Day) i8,888,1602,746,660
Average Daily Volume (90 Day) i5,961,5572,469,420
Shares Outstanding i173.41M122.29M
Float Shares i174.74M109.33M
% Held by Insiders i0.01%0.02%
% Held by Institutions i0.74%1.05%

Dividend Analysis & Yield Comparison: Teladoc Health vs 10x Genomics

MetricTDOCTXG
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A